Kura Oncology, Inc. (KURA) — Stock Score Summary

Kura Oncology, Inc. (KURA) has a MoatMap StockRank of 13/100 based on Quality (25/100), Value (32/100), and Momentum (40/100) factor scores. The current signal is STRONG SELL. Kura Oncology is an unprofitable biotech firm whose valuation relies entirely on binary clinical trial outcomes, which does not fit our risk-reward framework.

Kura Oncology is a clinical-stage biotechnology company dedicated to discovering and developing precision medicines for cancer, particularly targeting farnesyl transferase and other cancer pathways. Its competitive edge lies in proprietary drug candidates with novel mechanisms of action and a pipeline addressing significant unmet needs in oncology. The company's lead candidate, ziftomenib, is in late-stage clinical trials for acute myeloid leukemia (AML).

Key Financial Metrics

Price$8.81
Market Cap$885M
P/E (Forward)-3.30
Price/Book7.22
Return on Equity-124.7%
Return on Invested Capital-44.6%
Debt/Equity22.50
Gross Margin-263.9%
Operating Margin-431.5%
Revenue Growth29.5%
Free Cash Flow$-130M

Kura Oncology, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Kura Oncology, Inc.’s (KURA) StockRank?
MoatMap’s StockRank for Kura Oncology, Inc. (KURA) is 13/100, with a Strong Sell signal. It is a composite of Quality (25), Value (32), and Momentum (40) factor ranks across MoatMap’s 19,000+ stock universe.
Does Kura Oncology, Inc. have an economic moat?
Kura Oncology, Inc. (KURA) has a Quality factor score of 25/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Kura Oncology, Inc. a buy, hold, or sell?
MoatMap’s current signal for Kura Oncology, Inc. (KURA) is Strong Sell, based on a StockRank of 13/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Kura Oncology, Inc. in?
Kura Oncology, Inc. (KURA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksKURA deep dive reportAI ChampionsHow we score stocksSense-check another stock